# AngioDynamics and The PERT Consortium® Launch Investigator-Led Research Fund to Advance Pulmonary Embolism Care
Canonical URL: https://biopharmsignal.com/news/ANGO/angiodynamics-and-the-pert-consortiumr-launch-investigator-led-research-fund-to-advance-pulmonary-embolism-care
Ticker: ANGO
Company: AngioDynamics
Source: AngioDynamics
Published: 2026-02-05 13:00 EST
Original Source URL: https://investors.angiodynamics.com
## Summary

The ALPHA-PE Research Fund Supports Independent, Physician-Led Studies to Advance Real-World PE Evidence LATHAM, N.Y. --(BUSINESS WIRE)--Feb. 5, 2026-- AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s

## Article Body
The ALPHA-PE Research Fund Supports Independent, Physician-Led Studies to Advance Real-World PE Evidence LATHAM, N.Y. --(BUSINESS WIRE)--Feb. 5, 2026-- AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s
## Recent Company News
- 2026-05-28 17:25 EST — [AngioDynamics Expands Patient Access to NanoKnife IRE for Prostate and Liver Cancer as Medicare Coverage Framework Takes Effect](https://biopharmsignal.com/news/ANGO/angiodynamics-expands-patient-access-to-nanoknife-ire-for-prostate-and-liver-cancer-as-medicare-coverage-framework-takes-effect) — Source: AngioDynamics
- 2026-05-27 12:30 EST — [AngioDynamics to Present at the Goldman Sachs 47th Annual Global Healthcare Conference](https://biopharmsignal.com/news/ANGO/angiodynamics-to-present-at-the-goldman-sachs-47th-annual-global-healthcare-conference) — Source: AngioDynamics
- 2026-05-13 13:00 EST — [AngioDynamics Announces Two-Year PRESERVE Trial Data Demonstrating Durable NanoKnife IRE System Outcomes in Intermediate-Risk Prostate Cancer](https://biopharmsignal.com/news/ANGO/angiodynamics-announces-two-year-preserve-trial-data-demonstrating-durable-nanoknife-ire-system-outcomes-in-intermediate-risk-prostate-cancer) — Source: AngioDynamics
- 2026-04-02 10:00 EST — [AngioDynamics Reports Fiscal Year 2026 Third Quarter Financial Results; Sustained Double-Digit Med Tech Growth Drives Continued Profitability](https://biopharmsignal.com/news/ANGO/angiodynamics-reports-fiscal-year-2026-third-quarter-financial-results-sustained-double-digit-med-tech-growth-drives-continued-profitability) — Source: AngioDynamics
- 2026-03-31 12:00 EST — [AngioDynamics to Present at the 25th Annual Needham Virtual Healthcare Conference](https://biopharmsignal.com/news/ANGO/angiodynamics-to-present-at-the-25th-annual-needham-virtual-healthcare-conference) — Source: AngioDynamics
## Related News
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)
- 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c)
- 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)
- 2026-07-29 12:25 EST — ICCM — [IceCure: SIO Petitions NCCN to Include Cryoablation in Breast Cancer Treatment Guidelines, Citing IceCure's FDA Clearance  of ProSense®](https://biopharmsignal.com/news/ICCM/icecure-sio-petitions-nccn-to-include-cryoablation-in-breast-cancer-treatment-gu-bec46cd3)